Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;22(1):940.
doi: 10.1186/s12885-022-10039-y.

Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer

Kyoung Min Kim #  1 , Ae-Ri Ahn #  1 , Ho Sung Park  1 , Kyu Yun Jang  1 , Woo Sung Moon  1 , Myoung Jae Kang  1 , Gi Won Ha  2 , Min Ro Lee  2 , Myoung Ja Chung  3
Affiliations

Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer

Kyoung Min Kim et al. BMC Cancer. .

Abstract

In human colorectal cancer (CRC), TP53 is one of the most important driver genes. Immunohistochemistry (IHC) has been used most often to assess the variational status of TP53. Recently, next-generation sequencing (NGS) of the TP53 gene has increased. However, to our knowledge, a comparison between TP53 status evaluated by IHC and NGS has not been studied. Therefore, the primary aim of this study was to compare the clinical effect of TP53 status evaluated by IHC and NGS in patients with CRC. The secondary aim was to investigate the correlation between expression of p53 by IHC and variational status of TP53 by NGS. We performed immunohistochemical staining of p53 and sequencing of TP53 by NGS in 204 human samples of CRC. We then analyzed the correlation between variational status of TP53 and p53 expression, along with their prognostic impact in CRC patients. There was significant correlation between p53 expression and TP53 variation, TP53 variation and higher N stage, and positive p53 expression and higher N stage. Positive IHC expression of p53 was significantly associated with overall survival (OS) of CRC patients by univariate analysis and was revealed as an independent prognostic factor by multivariate analysis. Additionally, the nonsense/frameshift p53 expression pattern showed a significantly better prognosis than the wild type and missense p53 expression patterns. However, the variational status of TP53 was not significant in OS of CRC patients. These results suggest that IHC expression of p53 protein correlates with variation status of TP53 and expression of p53 protein rather than variation status of TP53 has more significant impact on the OS of CRC patients.

Keywords: Colorectal cancer; Immunohistochemistry; Next-generation sequencing; TP53.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Immunohistochemical expression of p53 in colorectal carcinoma tissue. We subdivided the p53 expression into nonsense/frameshift, wild type, and missense type pattern. The nonsense/frameshift pattern showing no expression, wild type pattern showing focal nuclear expression of p53, and missense pattern showing diffuse strong nuclear expression of p53 (original magnification: × 400)
Fig. 2
Fig. 2
Survival analysis according to variational status of TP53 and immunohistochemical expression of p53 in colorectal carcinoma patients. Kaplan-Meier survival curves for overall survival of colorectal carcinoma patients according to the immunohistochemical expression of p53 and variational status of TP53
Fig. 3
Fig. 3
Survival analysis after subclassifying the TP53 variation and immunohistochemical expression of p53 in colorectal carcinoma patients. Kaplan-Meier survival curves for overall survival after reclassifying the TP53 variation into nonsense/frameshift and missense variation and aberrant pattern of p53 expression into nonsense/frameshift and missense pattern
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;6(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Willett CG, Chang DT, Czito BG, Meyer J, Wo J. Cancer genome atlas network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337. doi: 10.1038/nature11252. - DOI - PMC - PubMed
    1. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15(4):857–865. doi: 10.1016/j.celrep.2016.03.075. - DOI - PMC - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2019;11(4):267–266. doi: 10.1093/jmcb/mjy075. - DOI - PMC - PubMed

Substances